<DOC>
	<DOC>NCT02396680</DOC>
	<brief_summary>The purpose of this study is to determine the efficacy of Ragweed-SPIRE 12 months after the initial dose.</brief_summary>
	<brief_title>Ragweed-SPIRE Follow-On Study</brief_title>
	<detailed_description />
	<mesh_term>Conjunctivitis</mesh_term>
	<criteria>Â° Previously randomised into and completed at least 6 of 8 treatment visits in Study TR006 Subject or Investigator have been informed of treatment received in Study TR006 Subjects with significant allergy to animal dander Any allergen immunotherapy since completing Study TR006 or use of prohibited therapies History of recurrent acute sinusitis or chronic sinusitis Received treatment with an investigational drug within 4 weeks of Screening Unable to understand study requirements or unable to communicate clearly with Investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Ragweed Allergy</keyword>
	<keyword>Rhinoconjunctivitis</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Ragweed-SPIRE</keyword>
</DOC>